Inotropic Stimulation Induces Cardiac Dysfunction in Transgenic Mice Expressing a Troponin T (I79N) Mutation Linked to Familial Hypertrophic Cardiomyopathy*

The cardiac troponin T (TnT) I79N mutation has been linked to familial hypertrophic cardiomyopathy and a high incidence of sudden death, despite causing little or no cardiac hypertrophy. In skinned fibers, I79N increased myofilamental calcium sensitivity (Miller, T., Szczesna, D., Housmans, P. R., Zhao, J., deFreitas, F., Gomes, A. V., Culbreath, L., McCue, J., Wang, Y., Xu, Y., Kerrick, W. G., and Potter, J. D. (2001)J. Biol. Chem. 276, 3743–3755). To further study the functional consequences of this mutation, we compared the cardiac performance of transgenic mice expressing either human TnT-I79N or human wild-type TnT. In isolated hearts, cardiac function was different depending on the Ca2+ concentration of the perfusate; systolic function was significantly increased in Tg-I79N hearts at 0.5 and 1 mmol/liter. At higher Ca2+ concentrations, systolic function was not different, but diastolic dysfunction became manifest as increased end-diastolic pressure and time to 90% relaxation.In vivo measurements by echocardiography and Doppler confirmed that base-line systolic function was significantly higher in Tg-I79N mice without evidence for diastolic dysfunction. Inotropic stimulation with isoproterenol resulted only in a modest contractile response but caused significant mortality in Tg-I79N mice. Doppler studies ruled out aortic outflow obstruction and were consistent with increased chamber stiffness. We conclude that in vivo, the increased myofilament Ca2+ sensitivity due to the I79N mutation enhances base-line contractility but leads to cardiac dysfunction during inotropic stimulation.

[1]  D. Szczesna,et al.  Abnormal Contractile Function in Transgenic Mice Expressing a Familial Hypertrophic Cardiomyopathy-linked Troponin T (I79N) Mutation* , 2001, The Journal of Biological Chemistry.

[2]  J. Seidman,et al.  Homozygous Mutation in Cardiac Troponin T: Implications for Hypertrophic Cardiomyopathy , 2000, Circulation.

[3]  N. Weissman,et al.  Remodelling of ionic currents in hypertrophied and failing hearts of transgenic mice overexpressing calsequestrin , 2000, The Journal of physiology.

[4]  M. Entman,et al.  Decreased left ventricular ejection fraction in transgenic mice expressing mutant cardiac troponin T-Q(92), responsible for human hypertrophic cardiomyopathy. , 2000, Journal of molecular and cellular cardiology.

[5]  M. Link,et al.  Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[6]  M. Davies,et al.  A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy , 1999, Heart.

[7]  R. Shemin,et al.  Immediate effect of aortic valve replacement for aortic stenosis on left ventricular diastolic chamber stiffness. , 1999, The American journal of cardiology.

[8]  T. Hewett,et al.  Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. , 1999, The Journal of clinical investigation.

[9]  Dimitrios Georgakopoulos,et al.  The pathogenesis of familial hypertrophic cardiomyopathy: Early and evolving effects from an α-cardiac myosin heavy chain missense mutation , 1999, Nature Medicine.

[10]  M. Frenneaux,et al.  Sudden death in hypertrophic cardiomyopathy: potential importance of altered autonomic control of vasculature , 1998, Heart.

[11]  J. Seidman,et al.  Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. , 1998, The Journal of clinical investigation.

[12]  H. Watkins,et al.  Sudden death due to troponin T mutations. , 1997, Journal of the American College of Cardiology.

[13]  J. Seidman,et al.  Electrophysiological abnormalities and arrhythmias in alpha MHC mutant familial hypertrophic cardiomyopathy mice. , 1997, The Journal of clinical investigation.

[14]  R. Meyer,et al.  Linear dependence of muscle phosphocreatine kinetics on oxidative capacity. , 1997, The American journal of physiology.

[15]  J. Seidman,et al.  Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy. Evidence for a dominant negative action. , 1996, The Journal of clinical investigation.

[16]  Frederick J. Schoen,et al.  A Mouse Model of Familial Hypertrophic Cardiomyopathy , 1996, Science.

[17]  J. Thomas,et al.  Determination of left ventricular chamber stiffness from the time for deceleration of early left ventricular filling. , 1995, Circulation.

[18]  W. Williams,et al.  Hypertrophic cardiomyopathy. Clinical spectrum and treatment. , 1995, Circulation.

[19]  R. Walsh,et al.  In vivo echocardiographic detection of enhanced left ventricular function in gene-targeted mice with phospholamban deficiency. , 1995, Circulation research.

[20]  J. Seidman,et al.  Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. , 1995, The New England journal of medicine.

[21]  R. Shemin,et al.  Increased left ventricular diastolic chamber stiffness immediately after coronary artery bypass surgery. , 1994, Journal of the American College of Cardiology.

[22]  V. Dilsizian,et al.  Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. , 1993, Journal of the American College of Cardiology.

[23]  J. Robbins,et al.  Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. , 1991, The Journal of biological chemistry.

[24]  J. Potter,et al.  The time-course of Ca2+ exchange with calmodulin, troponin, parvalbumin, and myosin in response to transient increases in Ca2+. , 1981, Biophysical journal.

[25]  A. Fabiato,et al.  Computer programs for calculating total from specified free or free from specified total ionic concentrations in aqueous solutions containing multiple metals and ligands. , 1988, Methods in enzymology.